 Kent Heyborne
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 13 | 2017 | 191 | 3.280 |
Why?
| | Premature Birth | 8 | 2023 | 301 | 2.620 |
Why?
| | Aspirin | 7 | 2017 | 348 | 2.380 |
Why?
| | Pregnancy | 61 | 2024 | 5922 | 2.380 |
Why?
| | Hydroxyprogesterones | 5 | 2017 | 7 | 2.330 |
Why?
| | Diabetes, Gestational | 3 | 2022 | 289 | 1.720 |
Why?
| | Pregnancy in Diabetics | 3 | 2022 | 88 | 1.710 |
Why?
| | Obstetric Labor, Premature | 5 | 2017 | 39 | 1.600 |
Why?
| | Pregnancy, Twin | 5 | 2023 | 22 | 1.520 |
Why?
| | Pregnancy Outcome | 9 | 2022 | 368 | 1.470 |
Why?
| | Fetal Membranes, Premature Rupture | 4 | 2020 | 38 | 1.420 |
Why?
| | Twins, Monozygotic | 4 | 2020 | 216 | 1.300 |
Why?
| | Prenatal Care | 4 | 2019 | 277 | 1.120 |
Why?
| | Pregnancy Complications, Infectious | 5 | 2023 | 301 | 1.070 |
Why?
| | Streptococcal Infections | 2 | 2019 | 145 | 1.020 |
Why?
| | Puerperal Disorders | 2 | 2022 | 34 | 0.960 |
Why?
| | Ultrasonography, Prenatal | 2 | 2023 | 242 | 0.900 |
Why?
| | Vasa Previa | 1 | 2023 | 3 | 0.900 |
Why?
| | Perinatal Death | 1 | 2023 | 23 | 0.890 |
Why?
| | Progesterone | 2 | 2023 | 243 | 0.890 |
Why?
| | Infant, Newborn | 20 | 2023 | 5456 | 0.880 |
Why?
| | Maternal Health Services | 2 | 2020 | 85 | 0.870 |
Why?
| | Female | 62 | 2024 | 64890 | 0.860 |
Why?
| | Infectious Disease Transmission, Vertical | 4 | 2022 | 160 | 0.850 |
Why?
| | Intracranial Pressure | 1 | 2023 | 55 | 0.850 |
Why?
| | Parturition | 1 | 2023 | 55 | 0.850 |
Why?
| | Gestational Age | 11 | 2022 | 797 | 0.820 |
Why?
| | Pregnancy Complications, Cardiovascular | 4 | 2014 | 72 | 0.810 |
Why?
| | Delivery, Obstetric | 5 | 2019 | 131 | 0.720 |
Why?
| | Cytomegalovirus Infections | 4 | 2023 | 194 | 0.710 |
Why?
| | Labor Stage, Second | 1 | 2019 | 5 | 0.680 |
Why?
| | Dystocia | 1 | 2019 | 10 | 0.670 |
Why?
| | Prediabetic State | 1 | 2022 | 241 | 0.670 |
Why?
| | Antibiotic Prophylaxis | 2 | 2019 | 101 | 0.660 |
Why?
| | Streptococcus agalactiae | 2 | 2019 | 90 | 0.650 |
Why?
| | Progestins | 2 | 2016 | 78 | 0.640 |
Why?
| | Pregnancy, Multiple | 5 | 2014 | 19 | 0.640 |
Why?
| | Chorionic Gonadotropin | 2 | 2016 | 81 | 0.630 |
Why?
| | Delivery Rooms | 1 | 2018 | 7 | 0.630 |
Why?
| | Urinalysis | 1 | 2018 | 69 | 0.610 |
Why?
| | Pregnancy Proteins | 2 | 2015 | 38 | 0.610 |
Why?
| | Body Mass Index | 4 | 2022 | 2174 | 0.600 |
Why?
| | Substance Abuse Detection | 1 | 2018 | 63 | 0.600 |
Why?
| | Cesarean Section | 2 | 2019 | 184 | 0.590 |
Why?
| | Caproates | 1 | 2017 | 4 | 0.590 |
Why?
| | Humans | 60 | 2024 | 125132 | 0.580 |
Why?
| | Birth Weight | 3 | 2017 | 477 | 0.580 |
Why?
| | Safety-net Providers | 1 | 2018 | 111 | 0.560 |
Why?
| | Chorion | 2 | 2020 | 8 | 0.560 |
Why?
| | Labor Onset | 1 | 2016 | 3 | 0.560 |
Why?
| | Fetal Macrosomia | 1 | 2017 | 60 | 0.560 |
Why?
| | Failure to Rescue, Health Care | 1 | 2016 | 1 | 0.560 |
Why?
| | Amnion | 2 | 2020 | 27 | 0.550 |
Why?
| | Spermatozoa | 1 | 2017 | 93 | 0.550 |
Why?
| | Fibronectins | 1 | 2017 | 119 | 0.540 |
Why?
| | T-Lymphocyte Subsets | 6 | 2001 | 406 | 0.540 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 304 | 0.520 |
Why?
| | Progesterone Congeners | 1 | 2015 | 15 | 0.520 |
Why?
| | Pregnancy Trimester, Second | 6 | 2016 | 75 | 0.470 |
Why?
| | Adult | 29 | 2022 | 33168 | 0.470 |
Why?
| | Congenital Abnormalities | 1 | 2015 | 80 | 0.460 |
Why?
| | Tissue and Organ Procurement | 1 | 2017 | 258 | 0.450 |
Why?
| | Physicians | 1 | 2022 | 836 | 0.440 |
Why?
| | Pregnancy Reduction, Multifetal | 2 | 2004 | 7 | 0.420 |
Why?
| | Pregnancy Complications | 3 | 2016 | 464 | 0.420 |
Why?
| | Twins | 5 | 2004 | 247 | 0.400 |
Why?
| | Guideline Adherence | 1 | 2016 | 563 | 0.400 |
Why?
| | Uterus | 4 | 2001 | 197 | 0.400 |
Why?
| | Smoking | 2 | 2017 | 1635 | 0.400 |
Why?
| | United States | 9 | 2022 | 13613 | 0.390 |
Why?
| | Hypertension | 3 | 2014 | 1257 | 0.390 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 5 | 1995 | 102 | 0.390 |
Why?
| | Prenatal Diagnosis | 2 | 2023 | 173 | 0.380 |
Why?
| | Retrospective Studies | 12 | 2023 | 13708 | 0.370 |
Why?
| | Hepatitis C | 2 | 2024 | 239 | 0.370 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1559 | 0.360 |
Why?
| | Amniotic Fluid | 4 | 2013 | 69 | 0.360 |
Why?
| | Perinatal Mortality | 4 | 2023 | 16 | 0.320 |
Why?
| | Killer Cells, Natural | 2 | 2001 | 389 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1280 | 0.300 |
Why?
| | Placenta | 6 | 2021 | 649 | 0.300 |
Why?
| | Tocolytic Agents | 1 | 2007 | 17 | 0.280 |
Why?
| | Magnesium Sulfate | 1 | 2007 | 20 | 0.280 |
Why?
| | Cervix Uteri | 3 | 2017 | 49 | 0.270 |
Why?
| | Obesity | 2 | 2016 | 2805 | 0.260 |
Why?
| | Fetal Monitoring | 1 | 2005 | 18 | 0.250 |
Why?
| | Placenta Growth Factor | 2 | 2015 | 26 | 0.240 |
Why?
| | Hepacivirus | 2 | 2024 | 240 | 0.240 |
Why?
| | Fetal Growth Retardation | 4 | 2005 | 477 | 0.240 |
Why?
| | Infant Mortality | 1 | 2005 | 95 | 0.230 |
Why?
| | Antigens, CD1 | 2 | 2001 | 59 | 0.230 |
Why?
| | Chorioamnionitis | 2 | 2015 | 38 | 0.230 |
Why?
| | Risk Factors | 9 | 2023 | 9549 | 0.220 |
Why?
| | Administration, Intravaginal | 1 | 2023 | 43 | 0.220 |
Why?
| | Pregnancy, Animal | 2 | 1994 | 58 | 0.220 |
Why?
| | Double-Blind Method | 3 | 2016 | 1725 | 0.210 |
Why?
| | Maternal Death | 1 | 2022 | 8 | 0.210 |
Why?
| | Pressure | 1 | 2023 | 237 | 0.200 |
Why?
| | Young Adult | 6 | 2018 | 11385 | 0.200 |
Why?
| | Cotinine | 1 | 2022 | 80 | 0.200 |
Why?
| | Trophoblasts | 2 | 1994 | 170 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2026 | 0.200 |
Why?
| | Fetal Proteins | 1 | 2001 | 20 | 0.190 |
Why?
| | Postpartum Hemorrhage | 1 | 2021 | 16 | 0.190 |
Why?
| | Obstetric Labor Complications | 1 | 2021 | 33 | 0.190 |
Why?
| | Embryo Implantation | 1 | 2000 | 24 | 0.180 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 1992 | 0.180 |
Why?
| | Hydrops Fetalis | 1 | 2000 | 14 | 0.180 |
Why?
| | Postpartum Period | 1 | 2022 | 289 | 0.170 |
Why?
| | Fetofetal Transfusion | 1 | 2020 | 23 | 0.170 |
Why?
| | Nicotine | 1 | 2022 | 289 | 0.170 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2001 | 176 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 187 | 0.170 |
Why?
| | Risk | 1 | 2022 | 896 | 0.170 |
Why?
| | Edema | 1 | 2000 | 131 | 0.160 |
Why?
| | Infant, Small for Gestational Age | 2 | 2017 | 81 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2000 | 311 | 0.160 |
Why?
| | Hearing Loss | 1 | 2022 | 195 | 0.160 |
Why?
| | Amniocentesis | 3 | 2022 | 25 | 0.160 |
Why?
| | Cohort Studies | 5 | 2020 | 5348 | 0.160 |
Why?
| | Morbidity | 1 | 2019 | 310 | 0.150 |
Why?
| | Biomarkers | 4 | 2022 | 3736 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1198 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3471 | 0.150 |
Why?
| | Histocompatibility, Maternal-Fetal | 1 | 2017 | 3 | 0.150 |
Why?
| | Cervical Length Measurement | 1 | 2017 | 3 | 0.150 |
Why?
| | Oocyte Donation | 1 | 2017 | 5 | 0.150 |
Why?
| | ROC Curve | 2 | 2016 | 501 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2017 | 35 | 0.140 |
Why?
| | Enoxaparin | 1 | 2017 | 55 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 484 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1191 | 0.130 |
Why?
| | Labor, Obstetric | 1 | 2016 | 58 | 0.130 |
Why?
| | Oocytes | 1 | 2017 | 194 | 0.130 |
Why?
| | Early Termination of Clinical Trials | 1 | 2015 | 15 | 0.130 |
Why?
| | Infant | 3 | 2024 | 8625 | 0.120 |
Why?
| | Decidua | 3 | 2001 | 27 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 110 | 0.120 |
Why?
| | Body Fluids | 1 | 2015 | 65 | 0.120 |
Why?
| | Tissue Donors | 1 | 2017 | 352 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2016 | 261 | 0.120 |
Why?
| | Male | 8 | 2022 | 60793 | 0.120 |
Why?
| | Fetal Development | 1 | 2017 | 254 | 0.120 |
Why?
| | Prevalence | 2 | 2022 | 2488 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 760 | 0.120 |
Why?
| | Endoglin | 1 | 2014 | 21 | 0.120 |
Why?
| | Embryonic and Fetal Development | 1 | 1994 | 96 | 0.120 |
Why?
| | Obstetrics | 1 | 2016 | 171 | 0.120 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 38 | 0.120 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2014 | 12 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2014 | 72 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 236 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1885 | 0.110 |
Why?
| | Logistic Models | 4 | 2022 | 2040 | 0.110 |
Why?
| | Blood Glucose | 1 | 2022 | 2008 | 0.110 |
Why?
| | Vagina | 1 | 2015 | 176 | 0.110 |
Why?
| | Anticoagulants | 1 | 2017 | 587 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2023 | 9790 | 0.110 |
Why?
| | Recurrence | 1 | 2015 | 1011 | 0.100 |
Why?
| | Interleukin-10 | 1 | 1994 | 311 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2014 | 368 | 0.100 |
Why?
| | Mass Screening | 1 | 2019 | 1119 | 0.100 |
Why?
| | Hypertension, Renovascular | 1 | 1991 | 16 | 0.100 |
Why?
| | Mice, Inbred C57BL | 7 | 2001 | 5102 | 0.100 |
Why?
| | Antigens, CD | 1 | 2014 | 466 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2001 | 1233 | 0.100 |
Why?
| | Renal Artery Obstruction | 1 | 1991 | 32 | 0.100 |
Why?
| | Ultrasonography | 1 | 2015 | 757 | 0.090 |
Why?
| | HIV Infections | 1 | 2024 | 2588 | 0.080 |
Why?
| | Fetal Death | 2 | 2020 | 57 | 0.080 |
Why?
| | T-Lymphocytes | 2 | 1995 | 1793 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1530 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 1990 | 188 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2015 | 710 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 1990 | 524 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 6818 | 0.060 |
Why?
| | Mice | 8 | 2001 | 15984 | 0.060 |
Why?
| | Proteomics | 2 | 2022 | 903 | 0.060 |
Why?
| | Syndrome | 2 | 2000 | 367 | 0.060 |
Why?
| | Child, Preschool | 1 | 2019 | 9938 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3274 | 0.060 |
Why?
| | Serum Albumin | 1 | 2005 | 153 | 0.060 |
Why?
| | Child | 2 | 2023 | 20014 | 0.060 |
Why?
| | Placental Insufficiency | 1 | 2005 | 104 | 0.060 |
Why?
| | California | 1 | 2005 | 385 | 0.050 |
Why?
| | Uterine Hemorrhage | 1 | 2023 | 37 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 155 | 0.050 |
Why?
| | Viremia | 1 | 2024 | 131 | 0.050 |
Why?
| | Hybridomas | 2 | 1993 | 233 | 0.050 |
Why?
| | Otoacoustic Emissions, Spontaneous | 1 | 2022 | 5 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2023 | 129 | 0.050 |
Why?
| | Maternal Mortality | 1 | 2022 | 33 | 0.050 |
Why?
| | Outpatients | 1 | 2005 | 347 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2022 | 153 | 0.050 |
Why?
| | Fathers | 1 | 2001 | 49 | 0.050 |
Why?
| | beta 2-Microglobulin | 1 | 2001 | 47 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2001 | 140 | 0.050 |
Why?
| | Inpatients | 1 | 2005 | 414 | 0.050 |
Why?
| | MEDLINE | 1 | 2000 | 26 | 0.050 |
Why?
| | Research Design | 1 | 2007 | 1035 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 137 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 394 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 147 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2013 | 1042 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 208 | 0.040 |
Why?
| | Infant, Premature | 2 | 2015 | 493 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2001 | 174 | 0.040 |
Why?
| | Animals | 8 | 2001 | 34345 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 2020 | 96 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 578 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2022 | 1561 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1008 | 0.040 |
Why?
| | Diseases in Twins | 1 | 1998 | 181 | 0.040 |
Why?
| | RNA | 1 | 2023 | 875 | 0.040 |
Why?
| | Case-Control Studies | 2 | 1994 | 3326 | 0.030 |
Why?
| | Sepsis | 2 | 2015 | 563 | 0.030 |
Why?
| | Leukomalacia, Periventricular | 1 | 2015 | 8 | 0.030 |
Why?
| | Mothers | 1 | 2001 | 740 | 0.030 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2015 | 31 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2015 | 82 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2015 | 58 | 0.030 |
Why?
| | Choriocarcinoma | 1 | 1994 | 9 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2015 | 133 | 0.030 |
Why?
| | Colorado | 1 | 2005 | 4471 | 0.030 |
Why?
| | Epidermis | 1 | 1995 | 152 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2001 | 2736 | 0.030 |
Why?
| | Cerebral Hemorrhage | 1 | 2015 | 102 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3047 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1993 | 9 | 0.030 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2015 | 106 | 0.030 |
Why?
| | Pregnancy-Specific beta 1-Glycoproteins | 1 | 1993 | 1 | 0.030 |
Why?
| | Fetal Distress | 1 | 1993 | 13 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 82 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2001 | 1778 | 0.030 |
Why?
| | DNA Primers | 1 | 1994 | 545 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1994 | 902 | 0.030 |
Why?
| | CD8 Antigens | 1 | 1992 | 72 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 837 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1144 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2001 | 2382 | 0.030 |
Why?
| | Antibody Diversity | 1 | 1992 | 17 | 0.030 |
Why?
| | Base Sequence | 2 | 1994 | 2207 | 0.030 |
Why?
| | Prognosis | 1 | 2000 | 3616 | 0.020 |
Why?
| | Middle Aged | 2 | 2004 | 29112 | 0.020 |
Why?
| | Immunophenotyping | 1 | 1992 | 286 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1995 | 870 | 0.020 |
Why?
| | Time Factors | 3 | 2015 | 6780 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 1992 | 566 | 0.020 |
Why?
| | Renal Artery | 1 | 1991 | 30 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 1992 | 121 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2926 | 0.020 |
Why?
| | Spleen | 1 | 1992 | 513 | 0.020 |
Why?
| | Angioplasty, Balloon | 1 | 1991 | 93 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 1995 | 781 | 0.020 |
Why?
| | Fetus | 1 | 1994 | 713 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 1994 | 1077 | 0.020 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 1990 | 18 | 0.020 |
Why?
| | Regression Analysis | 1 | 1992 | 1047 | 0.020 |
Why?
| | Triplets | 2 | 2000 | 5 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1994 | 713 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1992 | 1108 | 0.020 |
Why?
| | Hemolysis | 1 | 1990 | 166 | 0.020 |
Why?
| | Radiography | 1 | 1991 | 893 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2008 | 315 | 0.020 |
Why?
| | Peptides | 1 | 1992 | 884 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 381 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1993 | 2753 | 0.020 |
Why?
| | Glycation End Products, Advanced | 1 | 2005 | 72 | 0.010 |
Why?
| | Cysteine | 1 | 2005 | 188 | 0.010 |
Why?
| | Heat-Shock Proteins | 2 | 1994 | 129 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1872 | 0.010 |
Why?
| | Suture Techniques | 1 | 2000 | 137 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 19411 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2005 | 1210 | 0.010 |
Why?
| | Abruptio Placentae | 1 | 1998 | 4 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1993 | 170 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1994 | 533 | 0.010 |
Why?
| | Databases, Factual | 1 | 1998 | 1298 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 818 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2098 | 0.010 |
Why?
| | Cell Line | 1 | 1995 | 2806 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1992 | 638 | 0.000 |
Why?
| | Cytokines | 1 | 1995 | 1927 | 0.000 |
Why?
|
|
Heyborne's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|